Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02201797

Enrollment

Registered

2014-07-28

Start date

2014-10-31

Completion date

2015-06-30

Last updated

2015-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Liver Cancer

Keywords

Reproducibility of Results, Liver neoplasm, Neoplasm metastasis, Regional Perfusion, Perfusion Magnetic Resonance Imaging

Brief summary

Advanced MRI (Magnetic Resonance Imaging) technique called DCE (Dynamic Contrast Enhanced) and DWI MRI can provide valuable information regarding tumor biology and response to treatment through various parameters. Validating stability of these parameters will further establish robustness and reliability of these promising biomarkers.

Interventions

OTHERDCE MRI

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of metastatic liver cancer proven by pathology * At least one liver tumor should be \> 2cm in long diameter * Patients with viable tumor proven in the other imaging modalities

Exclusion criteria

* Severe claustrophobia * Presence of MRI-incompatible metallic objects or implanted medical devices in body * Renal failure, as determined by glomerular filtration rate (GFR) \< 30 mL/min/1.73 m2 * Weight greater than that allowable by the MRI table * Chemotherapy within 28 days prior to enrollment * Prior external radiation therapy to the liver, prior transarterial chemoembolization

Design outcomes

Primary

Measure	Time frame	Description
repeatability coefficient (RC)	one year	Repeatability coefficient of Ktrans, Kep, Ve, IAUGC60, and ADC value of the index tumor will be measured.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026